Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares dropped 0.9% during trading on Monday . The stock traded as low as $5.28 and last traded at $5.40. Approximately 3,541 shares were traded during trading, an increase of 64% from the average daily volume of 2,165 shares. The stock had previously closed at $5.45.
Graybug Vision Price Performance
The company’s fifty day moving average price is $4.71 and its 200 day moving average price is $4.29. The company has a market capitalization of $8.48 million, a P/E ratio of -0.22 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Articles
- Five stocks we like better than Graybug Vision
- What Do S&P 500 Stocks Tell Investors About the Market?
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- How to Read Stock Charts for Beginners
- A Hidden Gem Retailer With 20% Upside
- 3 REITs to Buy and Hold for the Long Term
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
